Treatment of diffuse large B‐cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10‐year results at a Latin American center

Jaime‐Pérez, José Carlos; Padilla-Medina, José Ramón; Salazar‐Cavazos, Lorena; Fernández, Lucía T; Gómez‐Almaguer, David

doi:10.1002/hon.2579

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported in the literature the risk of cardiotoxicity is significant in patients without risk factors therefore patients with signs of cardiac failure are preventively excluded from treatment with R‐CHOP. The attempt to use anthracyclines free regimen has not led to expected results 35,36 …”

Section: Discussionmentioning

confidence: 99%

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Rigacci

Annibali²,

Kovalchuk

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

Doxorubicin is the most effective single agent in the treatment of non-Hodgkin's lymphoma (NHL). Its use is limited because of the cardiac toxicity primarily in elderly patients (pts) and in pts with history of cardiac disease. Liposomal doxorubicin has been proven to reduce cardiotoxicity. The aim of this retrospective study was the use of nonpeghylated liposomal doxorubicin (NPLD) in term of efficacy, response rate and incidence of cardiac events. We retrospectively collected the experience of 33 Hematological Italian Centers in using NPLD. Nine hundred and forty-six consecu-How to cite this article: Rigacci L, Annibali O, Kovalchuk S, et al. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. Hematological

show abstract

Section: Discussionmentioning

confidence: 99%

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Rigacci

Annibali²,

Kovalchuk

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…In this regard, we have previously analyzed the treatment characteristics and clinical outcomes of patients with hematologic malignancies in Mexico, including those with ALL, AML, NHL, HL MM, and chronic myeloid leukemia. 31 -37 In most cases, results show suboptimal survival rates in comparison to high-income countries and the need to improve treatment strategies, which are considerably limited due to the financial restrictions in the low-income group being cared for at our public hospital, particularly with regard to incorporation of new highly effective pharmacologic and biological agents, which are beyond reach for this population; budget limitations also restrict state-of-the-art PC interventions.…”

Section: Discussionmentioning

confidence: 99%

Palliative Care for Patients With Hematologic Malignancies in a Low-Middle Income Country: Prevalence of Symptoms and the Need for Improving Quality of Attention at the End of Life

Jaime‐Pérez

Turrubiates-Hernández

Nava-Obregón

et al. 2019

Am J Hosp Palliat Care

Self Cite

View full text Add to dashboard Cite

Background: Palliative care (PC) for patients with malignant hematological diseases is scarcely documented, particularly in low- and middle-income countries. This study aimed to document PC provided to patients with hematologic malignancies. Methods: Bidirectional study conducted from July 2016 to June 2019 at the hematology and palliative care departments at a reference center in Northeast Mexico for low-income open population uninsured patients. Clinical records and electronic files of patients with malignant hematological diseases of both sexes and all ages attending an academic hematology center were reviewed. Statistical analysis was performed with the SPSS version 22 program. Acute and chronic leukemias, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and others were included. Results: Five-hundred ten patients were studied, of which 148 (29%) died. Eighty-one (15.88%) patients including 31 (20.9%) who died received PC. Median age at palliative diagnosis was 42 (2-91) years. The most common symptom was pain (69.7%). The most frequent reason for palliative referral was treatment-refractory disease (39%). During the last week of life, 19 (95%) of 20 patients had blood sampling; 17 (85%) received antibiotics; 16 (80%) had a urinalysis performed; 16 (80%) received analgesia, including paracetamol (11, 35.5%) and buprenorphine (7, 22.6%); 10 (50%) received blood products; 9 (45%) were intubated; and central venous catheters were inserted in 5 (25%) patients. Conclusions: Palliative care was provided to a minority of patients with hematologic malignancies and considerable improvement is required in its timely use and extension.

show abstract

“…Treatment protocols and outcomes for malignant hematology diseases in our population have been published [8][9][10][11][12][13][14][15][16] . For diagnosis and classification of the severity of AEs pertinent to this study, the Common Terminology Criteria for AEs v5.0 17 were used.…”

Section: Methodsmentioning

confidence: 99%

Incidence, severity, and outcome of adverse events to chemotherapeutic drugs used in hematological malignancies: Data from a reference center

Jaime‐Pérez¹,

García-Arellano²,

Turrubiates-Hernández³

et al. 2019

RMU

View full text Add to dashboard Cite

Objective:The aim of the study was to document the frequency, severity, evolution, and impact of adverse events (AE) on chemotherapy and the clinical evolution of patients with hematologic malignancies. Material and Methods: A prospective study was carried out at a hematology reference center in Northeastern Mexico over 1 year. All patients with malignant disease developing adverse chemotherapy events were included in the study. AEs were classified according to Common Terminology Criteria for AEs v5.0. Results: One-hundred and seventy-four patients attended the hematology clinic for outpatient chemotherapy. Acute lymphoblastic leukemia accounted for 51.7%, non-Hodgkin's lymphoma 25.9%, acute myeloid leukemia 9.8%, multiple myeloma 6.3%, Hodgkin's lymphoma 5.7%, and chronic myeloid leukemia 0.6% of the cases. A total of 191 AEs, including 79 hospital admissions, were registered in 58 (33.3%) patients. About 62.3% of the cases were Grade 3, in 43.9% of the events complete resolution was achieved, whereas the chemotherapy regimen had to be suspended in 13.6% of the cases. Febrile neutropenia was the main AE, documented in 77.6%; four (6.9%) patients died as a direct consequence of this complication. Thrombocytopenia occurred in 65.5% and anemia in 55.2%, with no deaths. Conclusions: AEs secondary to chemotherapeutic drugs used in the treatment of hematological malignancies constitute an important cause of morbidity and occasional mortality and should be closely monitored and documented.

show abstract

Treatment of diffuse large B‐cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10‐year results at a Latin American center

Cited by 3 publications

References 11 publications

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Palliative Care for Patients With Hematologic Malignancies in a Low-Middle Income Country: Prevalence of Symptoms and the Need for Improving Quality of Attention at the End of Life

Incidence, severity, and outcome of adverse events to chemotherapeutic drugs used in hematological malignancies: Data from a reference center

Contact Info

Product

Resources

About